Follistatin: Dosing Protocols

Research Dosing Disclaimer#

Follistatin gene therapy is investigational and available only through clinical trials. Recombinant follistatin protein is not approved for therapeutic use. This dosing information is provided for educational reference only.

Gene Therapy Dosing (Clinical Trials)#

Becker Muscular Dystrophy Trial#

The Phase 1/2a trial evaluated two dose levels of AAV1.CMV.huFS344 administered by direct intramuscular injection into both quadriceps muscles:

• Low dose: 3 x 10^11 vg/kg per leg (6 x 10^11 vg/kg total)
• High dose: 6 x 10^11 vg/kg per leg (1.2 x 10^12 vg/kg total)

The vector was delivered through multiple injection sites distributed across each quadriceps muscle to maximize transduction coverage. The high-dose cohort showed greater functional improvement, with one patient achieving a 108-meter improvement in the 6-minute walk test.

Inclusion Body Myositis Trial#

Six patients received AAV1.CMV.huFS344 at 6 x 10^11 vg/kg delivered to the quadriceps muscles of both legs. The injection procedure was similar to the BMD trial, with multiple injection sites per muscle.

Administration Considerations#

Gene Therapy Delivery#

AAV gene therapy administration requires specialized facilities and trained personnel. Key considerations include:

1. Pre-screening for anti-AAV1 antibodies (seropositive patients may have reduced transduction efficiency)
2. Controlled thawing of the frozen vector preparation
3. Multiple injection sites per muscle to ensure broad transduction
4. Post-injection monitoring for adverse events including immune responses
5. Long-term follow-up per regulatory requirements for gene therapy products

Recombinant Protein (Research)#

Recombinant follistatin protein has been studied in preclinical models via intravenous and subcutaneous routes. The short circulating half-life (2-4 hours) necessitates frequent dosing to maintain effective serum levels, which is impractical for chronic use and has driven the preference for gene therapy approaches.

Why Gene Therapy Over Protein?#

The gene therapy approach for follistatin has significant pharmacological advantages over recombinant protein administration:

Storage#

AAV gene therapy vectors must be stored at ultra-low temperatures (-80 degrees C or below) and handled according to strict chain-of-custody procedures. Recombinant follistatin protein should be stored lyophilized at -20 degrees C or below, with reconstituted solutions kept at 2-8 degrees C.

Dosing Context#

Follistatin belongs to the Musculoskeletal category of research peptides. Dosing protocols for Follistatin are derived from available clinical trial data. These protocols are provided for research reference only and do not constitute medical advice. Actual dosing decisions should be made by qualified healthcare providers based on individual patient factors.

Research Protocols#

The following dosing protocols have been documented in clinical research for Follistatin:

Gene therapy - BMD (low dose)#

Dose: 3 x 10^11 vg/kg per leg

Frequency: Single administration

Duration: Intended as one-time treatment

Bilateral intramuscular injection into quadriceps muscles

Gene therapy - BMD (high dose)#

Dose: 6 x 10^11 vg/kg per leg

Frequency: Single administration

Duration: Intended as one-time treatment

Higher dose showed greater functional improvement in Phase 1/2a trial

Gene therapy - inclusion body myositis#

Dose: 6 x 10^11 vg/kg total

Frequency: Single administration

Duration: Intended as one-time treatment

Bilateral quadriceps injection

Protocol Quick Reference#

Primary Use: Muscle growth via myostatin inhibition (gene therapy for muscular dystrophies; recombinant protein for research)

Dosing Summary: Gene therapy: 6 x 10^11 vg/kg per leg (single administration); Recombinant protein: 100-200 mcg SC daily administered Gene therapy: single administration; Recombinant protein: once daily for 10-30 day cycles for Gene therapy: one-time treatment; Recombinant protein: 10-20 days, repeated every 6 months.

Route of Administration: intramuscular (Gene therapy: single administration; Recombinant protein: once daily for 10-30 day cycles).

Timing Notes: No specific time of day for either approach

Cycle Duration: Gene therapy: one-time treatment; Recombinant protein: 10-20 days, repeated every 6 months.

Course-based protocol with rest periods

Reconstitution: Required.

Storage: AAV gene therapy vectors require storage at -80C or below. Recombinant follistatin protein should be stored lyophilized at -20C or below. Reconstituted solutions at 2-8C, use within specified timeframe.

Recommended Bloodwork#

Additional Considerations#

• Do NOT exceed 200 mcg/day; a case report showed visual impairment at 1 mg (10x recommended)
• Contraindication: Avoid in hormone-sensitive cancers, pregnancy, or women trying to conceive (FSH suppression affects fertility)

Reconstitution and Preparation#

AAV1-FS344 gene therapy vector is supplied as a frozen solution requiring controlled thawing per protocol. Recombinant follistatin protein (research grade) should be reconstituted in sterile buffer per manufacturer specifications.

Injection Sites#

Recommended injection sites for Follistatin include:

• Intramuscular (quadriceps, for gene therapy)
• Subcutaneous (recombinant protein, research)
• Intravenous (recombinant protein, research)

Site rotation is recommended to minimize local tissue reactions and ensure consistent absorption.

Storage Requirements#

AAV gene therapy vectors require storage at -80C or below. Recombinant follistatin protein should be stored lyophilized at -20C or below. Reconstituted solutions at 2-8C, use within specified timeframe.

Related Reading#

• Follistatin overview and research guide
• Follistatin side effects profile
• Follistatin research evidence